Hypotension is the most significant risk associated with the use of anti-hypertensive medica-tions. ACE inhibitors for example, and with combination of other anti-hypertensive drugs may result in reduction in preload and afterload. These drugs increase vasodilatory effects causing reduction in blood pressure. Risk factors include diabetes, more than 70 years of age and co-administration with other agents that affect the renin angiotensin aldosterone system (RAAS) such as ACE inhibitors and beta blockers (O’Donovan, 2014). Beta blocking agents is another example of anti-hypertensive drugs. The immediate effect is to reduce systolic blood pressure by 20 (mmHg) millimetre of mercury. Therefore, it is essential to take vital signs, including systolic
…show more content…
Furthermore, Mugosa et al. (2016) describe that polypharmacy is a common approach in cardiovascular pharmacology. It is the treatment of combining multiple classes of anti-hypertensive medications in con-junction with other medicines for synergistic effects for achieving blood pressure control. Conversely, patients taking cardiovascular drugs for a long period are at high risk for hypo-tension. Wang et al. (2015) report that bleeding is another potential risk for patient using low molecular weight heparin (LMWH). Moreover, bleeding is significantly associated with effect of drug. It reduces the ability of the blood to clot. By inhibiting clot formation by blocking the action of clotting factors or platelets in the blood. According to a study, the use of anti-hypertensive drugs and anti-clotting therapy is beneficial to prevent further recur-rence of ischaemic events and minimising the formation of potential blot clots. However, anti-coagulant medication can put patient at risk for bleeding. Health care professionals should be aware of the potential signs of bleeding and report to the clinician immediately Chaix et al.,
Furthermore, Mugosa et al. (2016) describe that polypharmacy is a common approach in cardiovascular pharmacology. It is the treatment of combining multiple classes of anti-hypertensive medications in con-junction with other medicines for synergistic effects for achieving blood pressure control. Conversely, patients taking cardiovascular drugs for a long period are at high risk for hypo-tension. Wang et al. (2015) report that bleeding is another potential risk for patient using low molecular weight heparin (LMWH). Moreover, bleeding is significantly associated with effect of drug. It reduces the ability of the blood to clot. By inhibiting clot formation by blocking the action of clotting factors or platelets in the blood. According to a study, the use of anti-hypertensive drugs and anti-clotting therapy is beneficial to prevent further recur-rence of ischaemic events and minimising the formation of potential blot clots. However, anti-coagulant medication can put patient at risk for bleeding. Health care professionals should be aware of the potential signs of bleeding and report to the clinician immediately Chaix et al.,